Longitudinal Health Report — n1.care sample report

Section 1

Clinical summary

SSituation · current trajectory

Read across three panels spanning eighteen months, this is a single, coherent metabolic trajectory in an otherwise well 58-year-old rather than a set of isolated abnormalities. The load-bearing thread is insulin resistance that has moved from borderline to established: HbA1c climbed 5.7 → 5.9 → 6.1%, fasting glucose crossed above range in mid-2025, and the derived HOMA-IR reached 5.0 at the latest panel.
Downstream of that thread, the atherogenic lipids widened (LDL 142 → 165 mg/dL, HDL falling below range), a fatty-liver enzyme signature emerged, and hs-CRP roughly doubled — all moving in the same direction and over the same window.

BBackground · record & sampling

Three fasting panels are on record — September 2024, June 2025, and March 2026 — with no documented diagnoses, medications, or supplements to complicate interpretation.
The consistency of the sampling interval makes the trajectory unusually clean to read: each marker below is anchored to the session at which it first crossed a threshold, so the movement is a real trend rather than single-panel noise.

AAssessment · clinical interpretation

MonitorThe dominant active process is progressive insulin resistance. HbA1c, fasting glucose and fasting insulin have all risen monotonically across the three panels, and the HOMA-IR of 5.0 is now well above the insulin-sensitive threshold of 2.0 — a reversible pre-diabetic pattern that is still short of diabetes.

MonitorVascular risk is widening beyond LDL alone: alongside a climbing LDL of 165 mg/dL, lipoprotein(a) of 78 nmol/L and homocysteine of 14.2 µmol/L add largely LDL-independent components that a single-panel lipid read would miss.

ObserveThe complete blood count, renal function and hepatic synthetic markers have stayed stable and in range throughout, so the metabolic drift has not yet spilled into other systems.

RRecommendation · concrete next steps

RecommendedBecause the downstream lipid, hepatic and inflammatory signals all trace back to the insulin-resistance thread, the trajectory argues for treating the upstream metabolic process now and staging hepatic and vascular risk before it consolidates — the later sections carry these forward as concrete steps.

Section 2

Clinical timeline

Sep 2024
The baseline panel already showed early metabolic drift — an above-range HbA1c and borderline atherogenic lipids — against an otherwise well profile.
HbA1cHigh at baseline→ Emerging dysglycaemia
HbA1c sat just above range at the first panel, marking the earliest sign of glycaemic drift.
LDL CholesterolHigh at baseline→ Atherogenic lipid pattern
LDL was already above target at baseline, establishing an atherogenic starting point.
TriglyceridesHigh at baseline→ Atherogenic lipid pattern
Triglycerides opened above range, consistent with early insulin-driven lipid handling.
hs-CRPHigh at baseline→ Low-grade inflammation
A mildly raised hs-CRP established a low-grade inflammatory backdrop from the outset.
Vitamin D, 25-OHLow at baseline→ Micronutrient status
Vitamin D was marginally low at baseline, the first of several modest micronutrient signals.
Jun 2025
By the interval panel the drift was consolidating: glycaemia and the hepatic enzymes stepped up, and fasting insulin crossed above range.
Fasting GlucoseCrossed above rangePrev: 98→ Emerging dysglycaemia
Fasting glucose moved from the high-normal baseline to frankly above range at this panel.
Fasting InsulinCrossed above rangePrev: 11→ Emerging dysglycaemia
Fasting insulin crossed above range, confirming the glycaemic change was insulin-driven.
Alanine Aminotransferase (ALT)Crossed above rangePrev: 48→ Hepatic steatosis signature
ALT crossed above range and above AST — the transaminase pattern typical of fatty liver.
hs-CRPStill elevatedPrev: 1.8→ Low-grade inflammation
hs-CRP continued to rise, tracking the widening metabolic load rather than any infection.
Mar 2026
The latest panel confirmed the trajectory: insulin resistance is now established, HDL has fallen below range, while the blood count and renal function stayed stable.
HbA1cTrending upPrev: 5.9→ Emerging dysglycaemia
HbA1c reached 6.1%, completing a consistent upward slope across all three panels.
HOMA-IRPeak valuePrev: 3.6→ Emerging dysglycaemia
The derived HOMA-IR reached 5.0, its highest value and well above the insulin-sensitive range.
HDL CholesterolCrossed below rangePrev: 43→ Atherogenic lipid pattern
HDL fell below the protective threshold, widening the atherogenic lipid picture.
HaemoglobinStable in range→ Blood count preserved
Haemoglobin held steady and in range, with no anaemia to complicate the metabolic picture.
eGFRStable→ Renal function preserved
Estimated GFR was unchanged and only mildly reduced for age, so renal function is preserved.

Section 3

Findings

Insulin resistance has consolidated across three panels

The clearest longitudinal signal is a steady progression into insulin resistance. HbA1c rose monotonically from 5.7% to 6.1%, fasting glucose from a high-normal 98 to 112 mg/dL, and fasting insulin from 11 to 18 µIU/mL, driving the derived HOMA-IR from 2.7 to 5.0. Read as a single trend rather than three separate flags, this is a reversible pre-diabetic trajectory that is still short of diabetes — which is precisely why the window to intervene is now. A confirmatory OGTT with paired insulin would stage it and set a clean pre-intervention baseline.

HbA1chigh

6.1%

Ref 4.0 - 5.6 % · 5.7 → 6.1

Fasting Glucosehigh

112mg/dL

Ref 70 - 99 mg/dL · 98 → 112

Fasting Insulinhigh

18µIU/mL

Ref 2 - 12 µIU/mL · 11 → 18

HOMA-IRhigh

5.0ref <2.0

The atherogenic lipid pattern is widening

The lipids have moved with the metabolic thread rather than independently. LDL climbed from 142 to 165 mg/dL, triglycerides from 168 to 210 mg/dL, and HDL fell from a protective 43 to a sub-range 38 mg/dL — the classic pattern of insulin-driven lipid handling. Two markers extend the risk beyond the standard panel: lipoprotein(a) at 78 nmol/L, a largely genetic and LDL-independent factor, and a homocysteine of 14.2 µmol/L. Because calculated LDL can under-read particle burden when triglycerides are high, an ApoB would refine both the risk and the treatment intensity.

LDL Cholesterolhigh

165mg/dL

Ref <100 mg/dL · 142 → 165

Triglycerideshigh

210mg/dL

Ref <150 mg/dL · 168 → 210

HDL Cholesterollow

38mg/dL

Ref >40 mg/dL · 43 → 38

Lipoprotein(a)high

78nmol/Lref <75

Homocysteinehigh

14.2µmol/Lref <10

A fatty-liver enzyme signature has emerged

A hepatic steatosis signature developed over the window. ALT crossed above range in mid-2025 and reached 62 U/L, exceeding AST (48 U/L), with GGT elevated at 74 U/L — a fat-pattern rather than a cholestatic or synthetic-failure picture, since alkaline phosphatase, bilirubin and albumin all stayed normal. Normal enzymes would not exclude fibrosis, and bloods alone cannot stage it, so imaging and a non-invasive fibrosis estimate are the logical next step.

Alanine Aminotransferase (ALT)high

62U/L

Ref 7 - 52 U/L · 48 → 62

Aspartate Aminotransferase (AST)high

48U/Lref 13 - 39

Gamma-GT (GGT)high

74U/Lref 8 - 61

Total Bilirubinin range

0.8mg/dLref 0.2 - 1.2

Low-grade inflammation is tracking the metabolic load

Inflammation has risen in step with the metabolic drift rather than pointing to infection. hs-CRP roughly doubled from 1.8 to 3.4 mg/L across the panels, with a mildly raised ESR and a persistently normal white-cell count. This is the signature of adipose-driven, cardiometabolic inflammation, and it predicts that the marker should fall as metabolic control improves — giving a convenient way to track response.

hs-CRPhigh

3.4mg/L

Ref <1.0 mg/L · 1.8 → 3.4

ESRhigh

18mm/hrref 0 - 15

White Blood Cell Countin range

6.810³/µLref 4.0 - 11.0

Section 4

Biomarker Trends

HbA1c is climbing through the pre-diabetic bandconcerningnegative trend

A monotonic 5.7 → 5.9 → 6.1% slope across three panels — each step small, but the direction unbroken. At this rate the diabetic threshold of 6.5% is roughly two years away without intervention.

Fasting glucose crossed above range in mid-2025concerningnegative trend

From a high-normal 98 mg/dL at baseline to 104 and then 112 mg/dL — the crossing is the event; the latest value confirms it was not single-panel noise.

Fasting insulin confirms the drift is insulin-drivenconcerningnegative trend

Rising from 11 to 18 µIU/mL alongside the glucose climb — the pairing is what establishes insulin resistance rather than isolated hyperglycaemia.

HOMA-IR has nearly doubled over the windowconcerningnegative trend

The derived index moved 2.7 → 3.6 → 5.0, now two and a half times the insulin-sensitive threshold of 2.0 — established, not borderline, resistance.

LDL is climbing on an already-elevated baseconcerningnegative trend

142 → 158 → 165 mg/dL against a <100 target. The trajectory matters as much as the level: this is not a stable elevated set-point but an active climb.

HDL has slipped below the protective thresholdconcerningnegative trend

43 → 40 → 38 mg/dL — a small absolute change, but it crossed the line that matters and completes the classic insulin-resistant lipid triad.

Triglycerides are rising in step with insulinconcerningnegative trend

168 → 190 → 210 mg/dL, tracking the insulin curve almost exactly — the most insulin-sensitive of the lipid markers, and the earliest to respond to intervention.

ALT crossed above range with a fatty-liver patternconcerningnegative trend

48 → 55 → 62 U/L, exceeding AST throughout — the transaminase pattern of hepatic steatosis rather than a cholestatic or synthetic process.

hs-CRP has doubled alongside the metabolic loadconcerningnegative trend

1.8 → 2.6 → 3.4 mg/L with a normal white-cell count throughout — adipose-driven inflammation, not infection, and a convenient marker to track reversal.

Vitamin D has drifted further below rangeconcerningnegative trend

29 → 26 → 24 ng/mL — modest, but moving the wrong way, and relevant to insulin sensitivity. One of the two low-risk repletion targets in the plan.

Section 5

Recommended follow-up

MEDIUMConfirm glucose handling with an OGTT and paired insulin

The three-panel trajectory establishes insulin resistance but cannot distinguish it from early beta-cell limitation — a distinction that shapes both prognosis and therapy. An oral glucose tolerance test with paired insulin, or a C-peptide, would settle that question and set a clean pre-intervention baseline. This is advised rather than urgent, because no value has reached a diabetic threshold; a repeat HbA1c at three months would run alongside it.

MEDIUMStage the composite vascular risk (ApoB, ambulatory BP)

With a climbing LDL, an elevated lipoprotein(a), a raised homocysteine and a borderline office blood pressure, an LDL-only view under-represents the risk. A formal 10-year risk estimate, an ApoB to quantify atherogenic particle burden, and an ambulatory blood-pressure record would let the true vascular burden be staged and a statin discussion be grounded in data rather than a single panel.

MEDIUMConfirm and stage the hepatic steatosis

The emerging ALT-over-AST pattern with a raised GGT justifies a liver ultrasound and a non-invasive fibrosis estimate such as FIB-4 or transient elastography. Normal albumin and bilirubin are reassuring for synthetic function but neither confirms nor stages steatosis, and the stage changes both surveillance and how aggressively to pursue metabolic reversal.

LOWRepeat the metabolic and lipid panels at three months

Because every headline marker is defined by its trend rather than a single value, a repeat metabolic and lipid panel at three months is the natural way to confirm the drift is reversing under intervention. A single follow-up panel showing the slope flattening would be the strongest evidence that the plan is working.

LOWRepair micronutrient status

Vitamin D has been low across the panels and magnesium sits just below range — each modest alone but relevant to insulin sensitivity and vascular tone, and both low-risk to correct. Repletion, with a recheck of B12 and folate in the context of the raised homocysteine, reinforces the primary metabolic and vascular goals rather than competing with them.

Section 6

Clinical background

The clinical backdrop is deliberately clean: a 58-year-old male with three fasting panels on record over eighteen months and no documented diagnoses, medications, supplements, or procedures. That absence is what makes the trajectory interpretable — the movement in HbA1c, glucose, insulin, lipids and the liver enzymes cannot be attributed to a new drug or an intercurrent illness, so it most plausibly reflects an underlying metabolic process. The gaps that remain are diagnostic rather than historical: there is no OGTT, no ApoB or particle count, no liver imaging, and only a single office blood pressure, each of which is addressed in the follow-up plan. A reconciled anthropometric record — weight, BMI and waist circumference — would further anchor the cardiometabolic reading.

Conditions

No conditions documented in this record.

Medications

No medications documented in this record.

Supplements

No supplements documented in this record.

Procedures

No procedures documented in this record.

Section 7

Data coverage

Coverage is strong where it matters most for a longitudinal read — three complete fasting panels at consistent intervals — and thin everywhere that would contextualise them. The gaps below are the same ones the follow-up plan addresses.

Area	Coverage	Note
Biomarker panels	good	Three complete fasting panels over 18 months at consistent intervals.
Glycaemic staging	partial	No OGTT or C-peptide; the insulin-resistance read rests on fasting values.
Lipid particle data	partial	No ApoB or particle count; calculated LDL may under-read particle burden.
Liver imaging	missing	No ultrasound or elastography; the steatosis signature is enzyme-only.
Blood pressure	partial	A single office reading; no ambulatory or home record.
Medications & history	missing	No documented medications, conditions, or procedures to reconcile.
Anthropometrics	missing	No weight, BMI, or waist circumference on record.

Section 8

References

American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20–S42. PMID: 38078589
Used in: Findings · Biomarker Trends — pre-diabetic banding of the HbA1c and fasting-glucose trajectory.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. PMID: 3899825
Used in: Findings — derivation and threshold for the HOMA-IR index.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946. PMID: 36036785
Used in: Findings · Recommended follow-up — LDL-independent risk carried by lipoprotein(a).
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. PMID: 36727674
Used in: Findings · Recommended follow-up — enzyme pattern, FIB-4 and imaging pathway for steatosis.
Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol. 2007;49(21):2129–2138. PMID: 17531663
Used in: Findings · Biomarker Trends — interpretation of the hs-CRP band for vascular risk.